Phibro Animal Health (PAHC) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY26 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance
February 4, 2026 4:25 PM ESTTEANECK, N.J.--(BUSINESS WIRE)-- Phibro Animal Health Corporation (Nasdaq: PAHC) (Phibro or the Company) today announced financial results for its second quarter ended December 31, 2025, and its updated financial guidance for the year ending June 30, 2026.
Highlights for the three months ended December 31, 2025 (compared to the three months ended December 31, 2024):
Net sales of $373.9 million, an increase of $64.6 million, or 21% Net income of $27.5 million, an increase of $24.3 million Diluted earnings per share of $0.67, an increase of $0.59 Adjusted EBITDA of $68.1 million, an increase of $19.9 million, or 41% Adjusted... More